Patents by Inventor Masatsugu Nakamura

Masatsugu Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200299098
    Abstract: A helical winding unit of a filament winding apparatus includes guide members guiding fiber bundles F to a liner, a movement mechanism moving the guide members, and a rotation mechanism rotating the guide members. Each of the guide members includes two side walls and guide portions fixed between the two side walls. As the guide portions, a first guide portion having a first guide surface and a second guide portion having a second guide surface and provided downstream of the first guide portion are provided. In the height direction, the first guide surface is oriented to one side. The second guide surface is oriented to the other side in the height direction and provided on the other side of the first guide surface.
    Type: Application
    Filed: August 10, 2018
    Publication date: September 24, 2020
    Inventors: Motohiro Tanigawa, Daigoro Nakamura, Hirotaka Wada, Tadashi Uozumi, Hideo Shitamoto, Tatsuhiko Nishida, Masatsugu Goyude, Tetsuya Matsuura, Shu Ikezaki
  • Publication number: 20200231403
    Abstract: A filament winding device includes a supporter configured to support a liner in a rotatable manner; a yarn supplying unit configured to support bobbins; a helical winding head configured to helical-wind a fiber bundles onto the liner; and a standard thread guiding mechanism configured to form a standard thread guide channel that guides a standard thread from the bobbins to the liner, the standard thread being different from the fiber bundles and being connected to leading ends of the fiber bundles, the standard thread guiding mechanism including nozzles configured to blow the standard thread with a compressed gas, and guide tubes configured to guide the standard thread blown by the nozzles, and the nozzles and the guide tubes being disposed along a fiber bundle guide channel, and capable of taking up the standard thread from the standard thread guide channel to the fiber bundle guide channel.
    Type: Application
    Filed: August 27, 2018
    Publication date: July 23, 2020
    Inventors: Motohiro Tanigawa, Daigoro Nakamura, Masatsugu Goyude, Tetsuya Matsuura, Hideo Shitamoto, Tatsuhiko Nishida, Tadashi Uozumi, Shu Ikezaki, Hirotaka Wada
  • Patent number: 10718329
    Abstract: A scroll compressor is provided which includes: a revolving scroll, a fixed scroll, an autorotation preventing mechanism, a frame, a crank shaft provided with an eccentric pin portion which is eccentric with respect to an axis, the crank shaft being provided with a flange portion at a lower portion of the eccentric pin portion, the flange portion being larger than the diameter of the eccentric pin portion, a balance weight mounted on the flange portion, a sealing member performing sealing between the revolving scroll and the flange portion, and a thrust bearing arranged between the frame and the flange portion. The scroll compressor reduces the amount of oil flowing into a back pressure chamber, thereby improving the performance of the scroll compressor.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 21, 2020
    Assignee: HITACHI-JOHNSON CONTROLS AIR CONDITIONG, INC.
    Inventors: Yasunori Nakano, Satoshi Nakamura, Takamasa Adachi, Masatsugu Chikano, Yuuichi Yanagase
  • Publication number: 20200215093
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10704471
    Abstract: Provided is a dump truck that includes an engine (1) and an ECU (7) controlling the engine (1) and that performs a predetermined operation after arriving at a destination. The ECU (7) is configured to makes larger an engine power suppression amount on a route leading the dump truck to the destination as a work waiting time that is a prediction time elapsing from an arrival of the dump truck at the destination to a start of the operation by the dump truck is longer and as an engine load of the dump truck is lower.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: July 7, 2020
    Assignee: Hitachi Construction Machinery Co., Ltd.
    Inventors: Akihiro Nakamura, Naokazu Oda, Masatsugu Arai
  • Publication number: 20200156483
    Abstract: A dump truck 100 including: an engine 1; a generator 10 driven by the engine 1; and a pair of driving wheels 3L and 3R arranged to the left and right of a vehicle body frame 7 includes: a traveling electric motor 12L including a plurality of electric motors 12La, 12Lb, and 12Lc that are coupled to the driving wheel 3L and simultaneously drive the driving wheel 3L; and a traveling electric motor 12R including a plurality of electric motors 12Ra, 12Rb, and 12Rc that are coupled to the driving wheel 3R and simultaneously drive the driving wheel 3R. Thereby, drive systems corresponding to loads of dump trucks or the like can be configured using identical components.
    Type: Application
    Filed: June 19, 2018
    Publication date: May 21, 2020
    Inventors: Satoru KANEKO, Shinji SUGIMOTO, Takayoshi NAKAMURA, Tadashi OSAKA, Masatsugu ARAI, Naoki FUKUDA
  • Patent number: 10632139
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 28, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20200085804
    Abstract: A composition for preventing or treating glaucoma or ocular hypertension including a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl} pyridin-2-ylamino) acetate and at least one other drug for preventing or treating glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
    Type: Application
    Filed: September 23, 2019
    Publication date: March 19, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko KIRIHARA, Atsushi SHIMAZAKI, Masatsugu NAKAMURA
  • Patent number: 10583743
    Abstract: In a regenerative braking device of a dump truck comprising an engine, a first generator and a second generator driven by the engine, at least one travel motor driven by generated electric power of the first generator and at least one fan motor to which generated electric power of the second generator is inputted via a first rectifier circuit, the regenerative braking device comprises: a resistive element to which regenerating electric power from the at least one travel motor in regenerative braking is supplied and which is cooled by at least one fan driven by the at least one fan motor and converts electric energy into heat energy and dissipates heat; and a DC/DC converter that inputs a part of the regenerating electric power which is supplied to the resistive element to an output line of the first rectifier circuit via a second rectifier circuit.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 10, 2020
    Assignee: Hitachi Construction Machinery Co., Ltd.
    Inventors: Tomonori Takada, Takanobu Ikari, Takashi Ikimi, Akihiro Nakamura, Masatsugu Arai, Naoki Fukuda, Takaaki Tanaka
  • Publication number: 20180353531
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10071113
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10002501
    Abstract: An electronic device includes a display unit 13, a panel 11, a tactile sensation providing unit 12 configured to vibrate a touch face of the panel 11, and a control unit 16 configured, when detecting contact to a tactile sensation providing area of the touch face corresponding to a predetermined word displayed on the display unit 13, to drive the tactile sensation providing unit 12 based on tactile sensation providing information associated with the predetermined word, such that a tactile sensation is provided to a contact object in contact with the tactile sensation providing area.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 19, 2018
    Assignee: KYOCERA Corporation
    Inventors: Masatsugu Nakamura, Yasuhiro Ueno
  • Publication number: 20170020910
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko SAKATANI, Tatsuo IKEI, Koji INAGAKI, Masatsugu NAKAMURA, Kazuhiro HOSOI, Mikiko SAITO, Masaki SONODA, Yoko FUKUI, Mitsuaki KUWANO
  • Patent number: 9542000
    Abstract: An object of the present invention is to provide corresponding tactile sensations in accordance with a characteristic of an image displayed. Specifically, an electronic device 10 according to the present invention includes a display unit 102 configured to display an image, a touch sensor 103 configured to detect a touch, a tactile sensation providing unit 104 configured to provide the tactile sensation to a touch face of the touch sensor 103, and a control unit 109 configured to divide the image into a plurality of areas and, when the touch sensor detects the touch to a position corresponding to any of the plurality of areas, to control the tactile sensation providing unit 104 to provide the tactile sensation associated with the area.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 10, 2017
    Assignee: KYOCERA Corporation
    Inventors: Yasuhiro Ueno, Masatsugu Nakamura
  • Patent number: 9486529
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 8, 2016
    Assignee: SANTEN PHARMCEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20160228421
    Abstract: A composition for preventing or treating glaucoma or ocular hypertension including a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl} pyridin-2-ylamino) acetate and at least one other drug for preventing or treating glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 11, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko KIRIHARA, Atsushi SHIMAZAKI, Masatsugu NAKAMURA
  • Patent number: 9339496
    Abstract: A composition for treating or preventing glaucoma or ocular hypertension including a isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate and a beta-receptor antagonist, in a combined pharmaceutically acceptable amount. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 17, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko Kirihara, Atsushi Shimazaki, Masatsugu Nakamura
  • Patent number: 9254306
    Abstract: An eye drop containing (i) a peptide having an amino acid sequence which is represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmaceutically acceptable salt thereof and (ii) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmaceutically acceptable salt thereof. The concentration ratio of the SSSR or a pharmaceutically acceptable salt thereof and the FGLM or a pharmaceutically acceptable salt thereof is 1/15 and 1/50. The concentration of the SSSR or a pharmaceutically acceptable salt thereof is 0.001% to 0.3% (w/v), and the concentration of the FGLM or a pharmaceutically acceptable salt thereof is 0.015% to 1.5% (w/v). The pH of the eye drop is 2.5 to 6.5. The eye drop serves to minimize the occurrence of side effects and serves to improve its storage stability.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: February 9, 2016
    Assignee: R-TECH UENO, LTD.
    Inventors: Takahiro Nakamura, Yuichiro Nakada, Takashi Nagano, Masatsugu Nakamura
  • Patent number: 9170472
    Abstract: According to an aspect, a portable photographing device includes: an image capturing unit; a projecting unit for projecting an image; and a storing unit for storing an image captured by the image capturing unit. The projecting unit projects any of a first image captured by the image capturing unit, a second image related to the first image, and a third image obtained by synthesizing the first image with the second image as a projection image into a region which is different from an image capturing region of the photographing unit. The storing unit stores the first image in the projection of the projection image or the first image after the projection of the projection image.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: October 27, 2015
    Assignee: KYOCERA CORPORATION
    Inventors: Yasuhiro Ueno, Yasushi Kitamura, Masatsugu Nakamura
  • Patent number: 9006208
    Abstract: An agent for treatment of dry eye comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: April 14, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Yuko Shichijo, Atsuyoshi Dota, Takashi Nagano, Masatsugu Nakamura, Asuka Sakamoto